Induction chemotherapy, response, and postremission therapy
| . | Total (n = 383) . | SD-DN arm (n = 189) . | HD-DN arm (n = 194) . | P . |
|---|---|---|---|---|
| Interim BM study after induction | ||||
| Blasts < 5% | 260 (67.9) | 114 (60.3) | 146 (75.3) | .002 |
| Blasts ≥ 5% | 111 (29.0) | 65 (34.4) | 46 (23.7) | |
| Unknown | 12 (3.1) | 10 (5.3) | 2 (1.0) | |
| CR with 1 course of induction | 244 (63.7) | 106 (56.1) | 138 (71.1) | .002 |
| Second course of induction | 111 (29.0) | 66 (34.9) | 45 (23.2) | .011 |
| Median interval between first and second course, d (range) | 17 (13-125) | 17 (13-62) | 18 (14-125) | .124 |
| CR after second course of induction | 52/111 (46.8) | 30/66 (45.5) | 22/45 (48.9) | .722 |
| Overall CR | 296 (77.3) | 136 (72.0) | 160 (82.5) | .014 |
| Reason for treatment failure | ||||
| Resistant | 67 (77.0) | 39 (73.6) | 28 (82.4) | .635 |
| Aplasia | 7 (8.0) | 5 (9.4) | 2 (5.9) | |
| Indeterminate | 13 (14.9) | 9 (17.0) | 4 (11.8) | |
| Postremission therapy | ||||
| No treatment | 4 (1.4) | 3 (2.2) | 1 (0.6) | .541 |
| Chemotherapy only | 149 (50.3) | 65 (47.8) | 84 (52.5) | |
| Allogeneic HCT | 138 (46.6) | 65 (47.8) | 73 (45.6) | |
| Autologous HCT | 5 (1.7) | 3 (2.2) | 2 (1.3) |
| . | Total (n = 383) . | SD-DN arm (n = 189) . | HD-DN arm (n = 194) . | P . |
|---|---|---|---|---|
| Interim BM study after induction | ||||
| Blasts < 5% | 260 (67.9) | 114 (60.3) | 146 (75.3) | .002 |
| Blasts ≥ 5% | 111 (29.0) | 65 (34.4) | 46 (23.7) | |
| Unknown | 12 (3.1) | 10 (5.3) | 2 (1.0) | |
| CR with 1 course of induction | 244 (63.7) | 106 (56.1) | 138 (71.1) | .002 |
| Second course of induction | 111 (29.0) | 66 (34.9) | 45 (23.2) | .011 |
| Median interval between first and second course, d (range) | 17 (13-125) | 17 (13-62) | 18 (14-125) | .124 |
| CR after second course of induction | 52/111 (46.8) | 30/66 (45.5) | 22/45 (48.9) | .722 |
| Overall CR | 296 (77.3) | 136 (72.0) | 160 (82.5) | .014 |
| Reason for treatment failure | ||||
| Resistant | 67 (77.0) | 39 (73.6) | 28 (82.4) | .635 |
| Aplasia | 7 (8.0) | 5 (9.4) | 2 (5.9) | |
| Indeterminate | 13 (14.9) | 9 (17.0) | 4 (11.8) | |
| Postremission therapy | ||||
| No treatment | 4 (1.4) | 3 (2.2) | 1 (0.6) | .541 |
| Chemotherapy only | 149 (50.3) | 65 (47.8) | 84 (52.5) | |
| Allogeneic HCT | 138 (46.6) | 65 (47.8) | 73 (45.6) | |
| Autologous HCT | 5 (1.7) | 3 (2.2) | 2 (1.3) |
Values are no. (%), unless otherwise stated.
BM indicates bone marrow.